Guest guest Posted March 6, 2007 Report Share Posted March 6, 2007 Dear FORUM, Ref: /message/6974 At the outset I thank Dr Bharti for his feedback. I totally agree with you that provisiong of ART has to be done carefully and scientifically by any Physician, whether is paid or in free roll out. The free roll out is never meant to compromise on quality of care or sensitiveness in treating PLHAs. NACO never starts a ART centre without training of faculty members from Medicine, paeds, gyane and dermatology departments. Alongwith this one medical officer, one counsellor, one satff nurse and one data manager is provided additionally to ART Centre by NACO. The medical officer undergoes a 12 days training before centre starts. All this is done to provide good quality care with a view to avoid drug resistance . The staff is also sensitized on issues of stigma and discrimination. As regards quality of drugs is concerned, only WHO prequalified or GMP companies medicines are procured following an International Competitive Bidding process and all drugs undergo pre supply and random post supply quality checks. No orders have been given to use lower doses of stavudine in case 40 mg has run short. Many a times as patients gain weight and require higher strength, there might be sometimes shortages for which drugs are shifted from other centres. I personally feel that doctors are hesistant to seek 2nd opinion in case they are in some difficult situation and this happens for any disease they are treating. We have to come out of this. ART information is available on some many websites and we have so many experienced persons in country that getting a opinion by email should be no problem. I will definately look into some of cases you have given. Such a feedback is not a crticism but helpful in increasing the levels of care to PLHAs to which all of us at NACO are committed Dr B.B.Rewari MD,FICP,FIACM,FIMSA Sr.Physician,Dr RML Hospital & National Programme Officer (ART) National AIDS Control Organistion (NACO) New Delhi Tel;23325343,23325335(O) FAX : 011-23731746 e-mail: <drbbrewari@...> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 6, 2007 Report Share Posted March 6, 2007 Dear FORUM, Re: /message/6975 Dr. Rewari is right that there are many physicians in India whose help can be saught if you face a dilemma in managing your patient on ART. but, rarely doctors take a second opinion. I have a HIV- II patient who went to Hinduja hospital for treatment. He was prescribed a AZT + LMV + EFV combination (CD-4 COUNT- 25 but still no significant symptoms) The patient took all the prscribed medicines for a month. When he was about to start the 2'nd month traement, he fortunately read the company's product monograph leaflet and realised that Efavir has no action against HIV II. He came to me saying that how can an MD physician (who was taking care of Late Pramod Mahajan) has no knowledge about this very basic. This is just one example. I have many a cases of mis- management by our doctor friends. Help is available at al the government set ups where patients who can afford to shell out money should be prescribed medicines and not enroled for free ART. Government, NGOs and individual volunteers ( who may be doctors) must promote this concept of -- " correct counseling and diagnosis-- is to undertaken only at recognised centers and qualified or a specially trained physician. " This HIV-ii patient is not on ART. After, drug sensitivity test from a recognised lab (as the patent can afford it), a PI based regimen with NRTIs combination would be considered after discussing the strategy of the treatment with the patient. Drug sequencing also might be a very big challange for him. Dr. Divya Mithel, Jyothis Care Center, Kalamboli e-mail: <d_mithel@...> Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.